CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors-Reference-Cited by-同舟云学术

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

Published:2019-09-05 Issue:1 Volume:10 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Jin Linchun^ORCID,Tao Haipeng,Karachi Aida,Long Yu,Hou Alicia Y.,Na Meng,Dyson Kyle A.^ORCID,Grippin Adam J.^ORCID,Deleyrolle Loic P.,Zhang Wang,Rajon Didier A.,Wang Qiong J.,Yang James C.^ORCID,Kresak Jesse L.,Sayour Elias J.,Rahman Maryam,Bova Frank J.,Lin Zhiguo,Mitchell Duane A.,Huang Jianping^ORCID

Funder

1. Wells Endowment 2. The Florida Center for Brain Tumor Research (FCBTR) and, Accelerate Brain Cancer Cure (ABC2) 3. UFHCC/ Wells BTC Pilot Award.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-019-11869-4.pdf

Reference51 articles.

1. Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813 (2017).

2. Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113 (2017).

3. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73–95ra73 (2011).